Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety

Experimental Biology and Medicine

Volumn 235, Issue 10, 2010, Pages 1163-1167

  Thorsell, Annika ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Anxiety; Corticotropin releasing hormone; Neuropeptide Y; Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR;

ADAPTIVE BEHAVIOR; ALCOHOLISM; ANXIETY DISORDER; BRAIN NUCLEUS; BRAIN REGION; CHRONIC DISEASE; CHRONIC STRESS; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEPENDENCE; EMOTION; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; MENTAL STRESS; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PROTEIN INTERACTION; SEDATION; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; BIOLOGICAL MODEL; BRAIN; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANIMALS; ANXIETY; BRAIN; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MODELS, NEUROLOGICAL; NEUROPEPTIDE Y; STRESS DISORDERS, TRAUMATIC; STRESS, PHYSIOLOGICAL;

EID: 77957826439     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.009331     Document Type: Conference Paper

References (90)

1. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000;886:172-89
2. Sapolsky RM. Physiological and pathophysiological implications of social stress in mammals. In: McEwen BS, Goodman HM, eds. Coping with the Environment: Neural and Endocrine Mechanisms. New York: Oxford University Press, 2001:517
3. Sapolsky RM. Endocrinology of the stress-response. In: Becker J, Breedlove S, Crews D, McCarthy M, eds. Behavioral Endocrinology. Cambridge, MA: MIT Press, 2002:409
4. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003;28:1735-42
5. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:52-8 (Pubitemid 27446270)
6. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001;24:97-129
7. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann NY Acad Sci 1998;840:33-44
8. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS, Heilig M. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol Psychiatry 2008;63:139-45 (Pubitemid 350299311)
9. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J. Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 1997;17:2605-14 (Pubitemid 27137426)
10. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
11. Hokfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991;7:867-79
12. Sajdyk TJ, Shekhar A, Gehlert DR. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 2004;38:225-34 (Pubitemid 39158861)
13. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990;15:71-100
14. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-7 (Pubitemid 12243637)
15. Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT, Koob GF. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994;11:179-86 (Pubitemid 24351285)
16. Koob GF. Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 1999;897:27-45
17. Rivier CL, Plotsky PM. Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion. Annu Rev Physiol 1986;48:475-94
18. Heinrichs SC, Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 2004;311:427-40
19. Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev Neurobiol 1996;10:155-68
20. Valentino RJ, Wehby RG. Corticotropin-releasing factor: evidence for a neurotransmitter role in the locus ceruleus during hemodynamic stress. Neuroendocrinology 1988;48:674-7
21. Schulkin J, Gold PW, McEwen BS. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology 1998;23:219-43 (Pubitemid 28352490)
22. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002;23:71-7
23. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002;2:23-33
24. Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 1999;408:365-77
25. Contarino A, Heinrichs SC, Gold LH. Understanding corticotropin releasing factor neurobiology: contributions from mutant mice. Neuropeptides 1999;33:1-12
26. Muller MB, Wurst W. Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med 2004;10:409-15
27. Britton DR, Koob GF, Rivier J, Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 1982;31:363-7
28. Swerdlow NR, Geyer MA, Vale WW, Koob GF. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) 1986;88:147-52
29. Britton KT, Morgan J, Rivier J, Vale W, Koob GF. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology (Berl) 1985;86:170-4
30. Liang KC, Melia KR, Campeau S, Falls WA, Miserendino MJ, Davis M. Lesions of the central nucleus of the amygdala, but not the paraventricular nucleus of the hypothalamus, block the excitatory effects of corticotropin-releasing factor on the acoustic startle reflex. J Neurosci 1992;12:2313-20
31. Pich EM, Heinrichs SC, Rivier C, Miczek KA, Fisher DA, Koob GF. Blockade of pituitary-adrenal axis activation induced by peripheral immunoneutralization of corticotropin-releasing factor does not affect the behavioral response to social defeat stress in rats. Psychoneuroendocrinology 1993;18:495-507
32. Britton KT, Lee G, Vale W, Rivier J, Koob GF. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res 1986;369:303-6
33. Korte SM, Eisinga W, Timmerman W, Nyakas C, Bohus B. Behavioral and cardiac responses after intracerebroventricular corticotropin-releasing hormone (CRH) administration: role of adrenal cortical hormones. Horm Behav 1992;26:375-84
34. Merali Z, McIntosh J, Kent P, Michaud D, Anisman H. Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central nucleus of the amygdala. J Neurosci 1998;18:4758-66
35. Merlo PE, Lorang M, Yeganeh M, Rodriguez de FF, Raber J, Koob GF, Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995;15:5439-47
36. Kalin NH, Takahashi LK, Chen FL. Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus. Brain Res 1994;656:182-6
37. Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA 1996;93:1619-23
38. Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD Jr. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999;156:585-8
39. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001;13:373-80
40. Ducottet C, Griebel G, Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:625-31
41. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-81
42. Adamec R, Fougere D, Risbrough V. CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD. Int J Neuropsychopharmacol 2009:1-11 [Epub ahead of print]
43. Strohle A, Scheel M, Modell S, Holsboer F, Blunted. ACTH response to dexamethasone suppression-CRH stimulation in posttraumatic stress disorder. J Psychiatr Res 2008;42:1185-8
44. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2, 6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 2007;27:2718-26
45. Olive MF, Koenig HN, Nannini MA, Hodge CW. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 2002;72:213-20
46. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton TK. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 1991;103:227-32
47. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659-60 (Pubitemid 12089070)
48. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 1982;79:5485-9
49. Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993;8:357-63 (Pubitemid 23162961)
50. Wahlestedt C, Yanaihara N, Håkanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 1986;13:301-7
51. Wahlestedt C, Hakanson R. Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre- and postjunctional receptors be distinguished? Med Biol 1986;64:85-8
52. Bard JA, Walker MW, Branchek TA, Weinshank RL. Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem 1995;270:26762-5
53. Schaffhauser AO, Stricker-Krongrad A, Brunner L, Cumin F, Gerald C, Whitebread S, Criscione L, Hofbauer KG. Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes 1997;46:1792-8
54. O'Shea D, Morgan DG, Meeran K, Edwards CM, Turton MD, Choi SJ, Heath MM, Gunn I, Taylor GM, Howard JK, Bloom CI, Small CJ, Haddo O, Ma JJ, Callinan W, Smith DM, Ghatei MA, Bloom SR. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 1997;138:196-202
55. Fuxe K, Agnati LF, Harfstrand A, Zini I, Tatemoto K, Pich EM, Hokfelt T, Mutt V, Terenius L. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 1983;118:189-92
56. Heilig M, Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul Pept 1987;19:221-31
57. Heilig M, Murison R. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. Eur J Pharmacol 1987;137:127-9
58. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. Behavioral effects of neuropeptide receptor agonists in the elevated plus-maze and fear-potentiated startle procedure. Behav Pharmacol 1995;6:215-22
59. Heilig M, Soderpalm B, Engel JA, Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989;98:524-9
60. Heilig M, McLeod S, Koob GF, Britton KT. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 1992;41:61-9
61. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993;259:528-31 (Pubitemid 23058713)
62. Heilig M. Antisense inhibition of neuropeptide Y (NPY) -Y1 receptor expression blocks the anxiolytic like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 1995;59:201-5
63. Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y-1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999;368:143-7
64. Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob GF. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997;132:6-13 (Pubitemid 27303733)
65. Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Pept 1998;75-6:247-54 (Pubitemid 28477534)
66. Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999;10:3003-7 (Pubitemid 29507769)
67. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 2000;97:12852-7
68. Thorsell A, Repunte-Canonigo V, O'Dell LE, Chen SA, King AR, Lekic D, Koob GF, Sanna PP. Viral vector-induced amygdala NPY overexpression reverses increased alcohol intake caused by repeated deprivations in Wistar rats. Brain 2007;130:1330-7
69. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, Virkkunen M, Mash DC, Lipsky RH, Hu XZ, Hodgkinson CA, Xu K, Buzas B, Yuan Q, Shen PH, Ferrel RE, Manuck SB, Brown SM, Hauger RL, Stohler CS, Zubieta JK, Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008;452:997-1001
70. Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjogren M, Asberg M, Ekman R, Wahlestedt C, Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004;38:113-21
71. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 1994;17:80-5 (Pubitemid 24033179)
72. Cannon WB. The James-Lange theory of emotion: a critical examination and an alternative theory. Am J Psychol 1927;39:106-24
73. Papez JW. A proposed mechanism of emotion. Arch Neurol Psychiatry 1937;79:217-24
74. Klüver H, Bucy PC. 'Psychic blindness' and other symptoms following bilateral temporal lobectomy in rhesus monkeys. Am J Physiol 1937;119:352-3
75. Klüver H, Bucy PC. Preliminary analysis of functions of the temporal lobes in monkeys. Arch Neurol Psychiatry 1939;42:979-1000
76. Brambilla P, Barale F, Caverzasi E, Soares JC. Anatomical MRI findings in mood and anxiety disorders. Epidemiol Psychiatr Soc 2002;11:88-99
77. Davidson RJ. The functional neuroanatomy of affective style. In: Lane RD, Nadel L, eds. In Cognitive Neuroscience of Emotion. New York: Oxford University Press, 2000:371
78. Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 1992;13:35-41
79. Sanders SK, Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995;52:701-6 (Pubitemid 3005245)
80. Moller C, Wiklund L, Sommer W, Thorsell A, Heilig M. Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions. Brain Res 1997;760:94-101
81. Amaral DG. The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety. Biol Psychiatry 2002;51:11-17
82. Lovenberg TW, Chalmers DT, Liu C, De Souza EB. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995;136:4139-42
83. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999;11:1431-48
84. Van PK, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000;428:191-212
85. Wolak ML, DeJoseph MR, Cator AD, Mokashi AS, Brownfield MS, Urban JH. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 2003;464:285-311
86. Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 1999;100:207-15
87. Sajdyk TJ, Gehlert DR. Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res 2000;877:226-34
88. Sajdyk TJ, Fitz SD, Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 2006;9:21-8
89. Sheriff S, Dautzenberg FM, Mulchahey JJ, Pisarska M, Hauger RL, Chance WT, Balasubramaniam A, Kasckow JW. Interaction of neuropeptide Y and corticotropin-releasing factor signaling pathways in AR-5 amygdalar cells. Peptides 2001;22:2083-9
90. Morris MJ, Pavia JM. Stimulation of neuropeptide Y overflow in the rat paraventricular nucleus by corticotropin-releasing factor. J Neurochem 1998;71:1519-24